These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24915808)

  • 21. [Comparison between analysis of HER2 gene and chromosome 17 in breast cancer by dual-probe chromogenic in situ hybridization and fluorescence in situ hybridization].
    Bai YF; Ren GP; Wang B; Teng LS; Liu X
    Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):161-5. PubMed ID: 20450761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Automated silver-enhanced in situ hybridization detection assay for human epidermal growth factor receptor 2 gene status determination in breast cancer].
    Ying JM; Guo L; Liu XY; Qiu T; Lü N
    Zhonghua Yi Xue Za Zhi; 2010 Jun; 90(24):1674-7. PubMed ID: 20979875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry].
    Shen DH; Wang FH; Yu YZ
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):457-60. PubMed ID: 17845758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.
    Brunelli M; Manfrin E; Martignoni G; Miller K; Remo A; Reghellin D; Bersani S; Gobbo S; Eccher A; Chilosi M; Bonetti F
    Am J Clin Pathol; 2009 May; 131(5):678-82. PubMed ID: 19369627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17.
    Torrisi R; Rotmensz N; Bagnardi V; Viale G; Curto BD; Dell'orto P; Veronesi P; Luini A; D'Alessandro C; Cardillo A; Goldhirsch A; Colleoni M
    Eur J Cancer; 2007 Nov; 43(16):2339-44. PubMed ID: 17855075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].
    Zhang GH; Shi DR; Liang XM; Hou JH; Kang SY; Zhu WD; Li XB; Shao Y; Chen LR; Zhou Y
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):580-3. PubMed ID: 17134562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
    Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
    JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance.
    Lambein K; Van Bockstal M; Vandemaele L; Geenen S; Rottiers I; Nuyts A; Matthys B; Praet M; Denys H; Libbrecht L
    Am J Clin Pathol; 2013 Oct; 140(4):561-6. PubMed ID: 24045554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer.
    Viale G
    J Pathol; 2009 Sep; 219(1):1-2. PubMed ID: 19670216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER2 overexpression of breast cancers in Hong Kong shows good concordance with HER2 amplification by fluorescence in-situ hybridisation study.
    Chan JK; Tsang WY; Lo ES; Wong MC
    Hong Kong Med J; 2008 Aug; 14(4):333; author reply 334. PubMed ID: 18685172
    [No Abstract]   [Full Text] [Related]  

  • 31. Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?
    Petroni S; Addati T; Mattioli E; Caponio MA; Quero C; Rubini V; Giotta F; Simone G
    Arch Pathol Lab Med; 2012 Sep; 136(9):993-1000. PubMed ID: 22938586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer.
    Zhu X; Lu Y; Lu H; Yang W; Tu X; Cai X; Zhou X
    Hum Pathol; 2011 Oct; 42(10):1499-504. PubMed ID: 21676436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of HER2 gene expression status in breast cancer by fluorescence in-situ hybridization].
    Zeng X; Zhao DC; Zhou WX; Wu SF; Liang ZY; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2005 Nov; 34(11):701-5. PubMed ID: 16536311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic Copy Number Analysis of HER2-Equivocal Breast Cancers.
    Geiersbach KB; Willmore-Payne C; Pasi AV; Paxton CN; Werner TL; Xu X; Wittwer CT; Gulbahce HE; Downs-Kelly E
    Am J Clin Pathol; 2016 Oct; 146(4):439-47. PubMed ID: 27614666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinicopathologic significance of chromosome 17 polysomy in breast cancer].
    Lü YL; Zhong M; Liu L; Wei LX; Zhao P
    Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):88-91. PubMed ID: 18681318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2 genetic heterogeneity in breast carcinoma.
    Ohlschlegel C; Zahel K; Kradolfer D; Hell M; Jochum W
    J Clin Pathol; 2011 Dec; 64(12):1112-6. PubMed ID: 22011446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluorescence in situ hybridization for detecting erbB-2 amplification in breast tumor fine needle aspiration biopsies.
    Sauter G; Feichter G; Torhorst J; Moch H; Novotna H; Wagner U; Dürmüller U; Waldman FM
    Acta Cytol; 1996; 40(2):164-73. PubMed ID: 8629392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Analysis of HER2 status in breast carcinoma using fully automated HER2 staining and fluorescence in-situ hybridization technology].
    Ying JM; Liu XY; Guo L; Xie YQ; Lü N
    Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):296-300. PubMed ID: 22883666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?
    Bartlett JM; Campbell FM; Mallon EA
    Am J Clin Pathol; 2008 Dec; 130(6):920-6. PubMed ID: 19019769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current ASCO / CAP 2013 recommendations for testing for HER2 status in breast cancer].
    Snietura M; Lange D
    Pol J Pathol; 2014 Dec; 65(4 Suppl 2):S32-41. PubMed ID: 26165042
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.